Published in Eur J Med Chem on April 14, 2009
Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis (2010) 1.12
Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase. Pharmaceuticals (Basel) (2010) 0.75
Pharmacological properties of indazole derivatives: recent developments. Mini Rev Med Chem (2005) 1.77
[Assessment of core capacities for enforcement of the International Health Regulations at points of entry in Uruguay]. Rev Panam Salud Publica (2011) 1.65
Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini Rev Med Chem (2005) 1.41
[Measuring breathing pattern in patients with chronic obstructive pulmonary disease by electrical impedance tomography]. Arch Bronconeumol (2009) 1.38
Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [VVO2(5-bromosalicylaldehyde semicarbazone)]. J Inorg Biochem (2005) 1.06
Synthesis, isomer characterization, and anti-inflammatory properties of nitroarachidonate. Biochemistry (2007) 1.05
Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J Med Chem (2006) 1.00
Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochem Pharmacol (2010) 0.97
New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. J Inorg Biochem (2007) 0.97
Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr (2007) 0.94
Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther (2006) 0.92
Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-Trypanosoma cruzi activity. J Inorg Biochem (2008) 0.91
New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies. Bioorg Med Chem (2009) 0.90
Routine chest roentgenogram after central venous catheter insertion is not always necessary. Am J Surg (2003) 0.90
Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. Bioorg Med Chem (2007) 0.90
Chemotherapy of Chagas' disease: status and new developments. Curr Top Med Chem (2002) 0.90
4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity. Eur J Med Chem (2007) 0.89
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies. Eur J Med Chem (2009) 0.88
In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles. Eur J Med Chem (2008) 0.87
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives. J Med Chem (2012) 0.87
Physico-chemical characterisation and biological evaluation of 188-Rhenium colloids for radiosynovectomy. BMC Nucl Med (2002) 0.87
Risedronate metal complexes potentially active against Chagas disease. J Inorg Biochem (2010) 0.87
Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase. J Biol Inorg Chem (2008) 0.85
Impact of vaccination against Haemophilus influenzae type b with and without a booster dose on meningitis in four South American countries. Vaccine (2011) 0.85
In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorg Med Chem (2004) 0.85
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships. Bioorg Med Chem (2009) 0.84
Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicol Lett (2009) 0.84
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg Med Chem (2008) 0.84
Platinum(II) metal complexes as potential anti-Trypanosoma cruzi agents. J Inorg Biochem (2007) 0.84
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity. J Med Chem (2014) 0.84
Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins. J Med Chem (2005) 0.83
Indazole N-oxide derivatives as antiprotozoal agents: synthesis, biological evaluation and mechanism of action studies. Bioorg Med Chem (2006) 0.82
188Re radiopharmaceuticals for radiosynovectomy: evaluation and comparison of tin colloid, hydroxyapatite and tin-ferric hydroxide macroaggregates. BMC Nucl Med (2004) 0.82
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg Med Chem (2009) 0.82
Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol (2008) 0.82
Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data. Vaccine (2013) 0.82
Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. Dalton Trans (2012) 0.82
Short-term lipid changes associated with highly active antiretroviral therapy in naive HIV-infected patients. J Acquir Immune Defic Syndr (2003) 0.82
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. Bioorg Med Chem (2008) 0.82
Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg Med Chem (2007) 0.81
Cytotoxicity of furoxans: quantitative structure-activity relationships study. Farmaco (2004) 0.81
Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. Eur J Med Chem (2010) 0.81
Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report. Int J Hematol (2005) 0.81
Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case-control study. AIDS (2003) 0.81
Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg Med Chem Lett (2004) 0.81
Development of hypoxia selective cytotoxins for cancer treatment: an update. Med Chem (2006) 0.81
Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 0.81
Identification of thioredoxin glutathione reductase inhibitors that kill cestode and trematode parasites. PLoS One (2012) 0.81
[(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model. Oncology (2013) 0.81
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies. J Med Chem (2011) 0.81
Evaluating 5-nitrofurans as trypanocidal agents. Antimicrob Agents Chemother (2013) 0.80
Antiparasitic prodrug nifurtimox: revisiting its activation mechanism. Future Microbiol (2011) 0.80
Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: Substituents-clustering methodology in the search for new active compounds. Bioorg Med Chem (2005) 0.80
Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma. Eur J Med Chem (2010) 0.80
Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins. Eur J Med Chem (2005) 0.80
1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part III. Arch Pharm (Weinheim) (2004) 0.80
ESR spin trapping studies of free radicals generated from nitrofuran derivative analogues of nifurtimox by electrochemical and Trypanosoma cruzi reduction. Free Radic Res (2003) 0.80
A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors. Dalton Trans (2013) 0.80